Breaking News

Merck Completes Acquisition of Verona Pharma

Strengthens Merck’s cardio-pulmonary portfolio with the addition of Ohtuvayre.

Author Image

By: Charlie Sternberg

Associate Editor

Merck has completed its previously announced acquisition of Verona Pharma plc. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. The total transaction value was approximately $10 billion. “The Verona Pharma acquisition strengthens and complements our portfolio of treatments for patients with cardio-pulmonary diseases to include Ohtuvayre, while delivering near and lo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters